|Bid||131.45 x 100|
|Ask||131.79 x 100|
|Day's Range||129.94 - 132.88|
|52 Week Range||96.70 - 138.89|
|Beta (3Y Monthly)||0.66|
|PE Ratio (TTM)||47.47|
|Earnings Date||Feb 11, 2019 - Feb 15, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||140.67|
Charles River Laboratories International, Inc. (CRL) today announced new additions to the Tumor Model Compendium. Charles River’s Compendium provides access to a comprehensive collection of well-established tumor models for early-stage oncology research. The most recent Compendium update adds gastric and liver models, as well as new molecular data for leukemia, liver cancer, lymphoma, breast cancer and ovarian cancer.
Looking at Charles River Laboratories International Inc’s (NYSE:CRL) earnings update in June 2018, it seems that analyst forecasts are substantially optimistic, with profits predicted to ramp up by an impressive Read More...
Charles River (CRL) delivered earnings and revenue surprises of 10.87% and 3.12%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Wilmington, Massachusetts-based company said it had net income of $1.22 per share. Earnings, adjusted for one-time gains and costs, were $1.53 per share. The results surpassed Wall Street expectations. ...
Charles River Laboratories International, Inc. (CRL) today announced that its team of neuroscience drug discovery experts will present 26 scientific posters, both independently and collaboratively with clients, at Neuroscience 2018, the 48th annual meeting of the Society for Neuroscience (SfN). Throughout the conference, Charles River experts will be presenting posters and hosting discussions on the latest innovations in neuroscience research, including innovative tools and applications for research on drugs targeting Huntington’s, Alzheimer’s, Parkinson’s, Multiple Sclerosis, and other neurological disorders.
NEW YORK, Oct. 29, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
New partnership allows Charles River’s clients access to Distributed Bio’s antibody discovery platforms
Charles River Laboratories International, Inc. (CRL) today announced that it was awarded a five-year, $95.7 million contract by the National Institute of Allergy and Infectious Diseases (NIAID), which is one of the largest institutes of the National Institutes of Health (NIH). Under NIAID’s Division of Intramural Research animal care program, Charles River will manage and provide staffing for NIAID’s on-site vivarium and related research model operations. The program is required to ensure the humane care and use of research models, and the efficient management of NIAID’s research model operations.
Charles River Laboratories International, Inc. will release third-quarter 2018 financial results on Wednesday, November 7th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, November 7th, at 8:30 a.m.
The New York Times previously reported Thompson's resignation from Merck and from lab services company Charles River Laboratories International Inc. The move follows the resignation of Sloan Kettering's chief medical officer, Jose Baselga, in September, after a New York Times and Pro Publica investigation revealed that he had not disclosed millions of dollars in payments from health-care companies in many of his research articles.
This article is intended for those of you who are at the beginning of your investing journey and want to learn about Return on Equity using a real-life example. CharlesRead More...
Charles River Laboratories International, Inc. announced today that it will present at three upcoming investor conferences, including:
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...
Charles River (CRL) delivered earnings and revenue surprises of 10.96% and 2.77%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Wilmington, Massachusetts-based company said it had profit of $1.10. Earnings, adjusted for one-time gains and costs, came to $1.62 per share. The results beat Wall Street expectations. ...
Tenet Healthcare (THC) is likely to repeat its success story in Q2 on the back of a strong performance at the Conifer segment as well as its key initiatives.